Enovis Corporation (NYSE:ENOV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enovis Corporation (NYSE:ENOV) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $44.50.

Several analysts have issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. William Blair initiated coverage on Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Finally, Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday.

Enovis Stock Up 0.4%

NYSE ENOV opened at $22.60 on Monday. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. Enovis has a 52 week low of $19.14 and a 52 week high of $36.82. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.14 and a beta of 1.39. The company has a fifty day moving average of $23.23 and a two-hundred day moving average of $23.84.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the prior year, the firm posted $0.81 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts predict that Enovis will post 3.12 earnings per share for the current year.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have bought 4,200 shares of company stock valued at $92,084 over the last ninety days. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enovis

Several hedge funds have recently modified their holdings of ENOV. Vanguard Group Inc. increased its holdings in Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after buying an additional 125,460 shares during the period. Dimensional Fund Advisors LP boosted its position in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after acquiring an additional 51,201 shares in the last quarter. Rubric Capital Management LP purchased a new position in shares of Enovis in the 3rd quarter valued at $83,435,000. Paradigm Capital Management Inc. NY increased its holdings in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after acquiring an additional 732,917 shares during the period. Finally, River Road Asset Management LLC raised its position in shares of Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after acquiring an additional 46,289 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.